CD19 CAR T-cell therapy shows promise in treating severe rheumatoid arthritis with sustained clinical improvement
CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis showed clinical safety and efficacy in a phase 1 trial published in Nature Medicine on August 27, 2026. Evaluating mivocabtagene … Read More